 "Daiichi Sankyo’s R&D unit in India")
Japanese pharmaceutical company Daiichi Sankyo Company Limited has decided to close its Gurgaon (Haryana) based research subsidiary, Daiichi Sankyo India Pharma Private Limited (DSIN), to increase its R&D productivity.
Daiichi Sankyo is reviewing its global R&D system with the aim of decreasing R&D operations costs and redistributing resources to the further development of its R&D pipeline.
DSIN presently employs approximately 170 people, mainly engaged in conducting drug discovery research targeting infectious diseases and inflammation. Following its closure, the DSIN R&D pipeline - including research themes selected by the Global Health Innovative Technology Fund (GHIT Fund) - will be transferred to Daiichi Sankyo’s
